Join to View Full Profile
7601 Canby AveSte 7Reseda, CA 91335
Phone+1 818-757-1919
Fax+1 818-757-3134
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Ilya Rachman, MD is an internist in Reseda, California. He is currently licensed to practice medicine in California.
Education & Training
University of Illinois College of MedicineClass of 2000
Certifications & Licensure
CA State Medical License 2002 - 2028
Publications & Presentations
PubMed
- 73 citationsNanomedicine based curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles: In vitro evaluation on 2D and 3D tumor models.Can Sarisozen, Shekhar Dhokai, Edcar G. Tsikudo, Ed Luther, Ilya M. Rachman
European Journal of Pharmaceutics and Biopharmaceutics. 2016-11-01 - 44 citationsAnti-cancer activity of anti-GLUT1 antibody-targeted polymeric micelles co-loaded with curcumin and doxorubicinAbraham H. Abouzeid, Niravkumar R. Patel, Ilya M. Rachman, Sean Senn, Vladimir P. Torchilin
Journal of Drug Targeting. 2013-10-28 - 12 citationsLupron-induced maniaMichael Rachman, David A. S. Garfield, Ilya M. Rachman, Rochelle S. Cohen
Biological Psychiatry. 1999-01-15
Press Mentions
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL AmyloidosisDecember 7th, 2025- Immix Biopharma : Presentation (IMMX Corporate Presentation – November 2025)December 2nd, 2025
- Immix Biopharma Announces Primary Endpoint Met in Positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL AmyloidosisJune 3rd, 2025
